TherapeuticsMD (TXMD) Cost of Revenue (2011 - 2023)

TherapeuticsMD has reported Cost of Revenue for 13 years, with the latest figure at $106000.0 in Q3 2023.

• For the quarter ending Q3 2023, Cost of Revenue fell 70.06% year-over-year to $106000.0; the trailing twelve-month figure through Dec 2023 stood at $106000.0 (down 92.41% YoY), and the FY2022 full-year result was $1.4 million, changed 0.36% from the prior year.
• Cost of Revenue for Q3 2023 stood at $106000.0, down from $354000.0 in the prior quarter.
• The five-year high for Cost of Revenue was $30.0 million in Q3 2021, with the low at -$84.8 million in Q4 2021.
• Historically, Cost of Revenue has averaged $1.1 million across 5 years, with a median of $2.1 million in 2019.
• The largest YoY upside for Cost of Revenue was 815.07% in 2021 against a maximum downside of 426.17% in 2021.
• TherapeuticsMD's Cost of Revenue stood at $2.9 million in 2019, then soared by 802.95% to $26.0 million in 2020, then sank by 426.17% to -$84.8 million in 2021, then soared by 100.42% to $354000.0 in 2022, then plunged by 70.06% to $106000.0 in 2023.
• The last three Cost of Revenue figures came in at $106000.0 (Q3 2023), $354000.0 (Q3 2022), and $348000.0 (Q2 2022), per Business Quant data.